HPN-217 is a monoclonal antibody commercialized by Harpoon Therapeutics, with a leading Phase II program in Refractory Multiple Myeloma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of HPN-217’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for HPN-217 is expected to reach an annual total of $111 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

HPN-217 Overview

HPN-217 is under development for the treatment of relapsed and refractory multiple myeloma. The drug candidate is a tri-specific antibody and T cell engager. It has three binding domains, one arm bind to cancer cells, second arm to capture and engage bypassing T cells and third arm bind to human serum albumin. It acts by targeting B cell maturation antigen (BCMA) and CD3. It is developed based on tri-specific T-cell Activating Construct (TriTAC) platform. It is administered through intravenous route.

It was also under development for mantle cell lymphoma.

Harpoon Therapeutics Overview

Harpoon Therapeutics (Harpoon) is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company’s pipeline products include HPN536 against ovarian cancer, HPN217 targeting Multiple Myeloma, HPN328 indicated for small cell lung cancer; and HPN601, is a protease-activated EpCAM targeting T cell engager for the treatment of solid tumors. It utilizes Tri-specific T cell activating construct (TriTAC) platform, for developing a pipeline of novel T cell engagers designed for targeted penetration and destruction of solid tumors and hematologic malignancies. Harpoon is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$31.9 million for the fiscal year ended December 2022 (FY2022), an increase of 34.9% over FY2021. The operating loss of the company was US$68.3 million in FY2022, compared to an operating loss of US$116.8 million in FY2021. The net loss of the company was US$67.7 million in FY2022, compared to a net loss of US$116.7 million in FY2021. The company reported revenues of US$4.5 million for the third quarter ended September 2023, a decrease of 78% over the previous quarter.

For a complete picture of HPN-217’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.